We further identified additional patients with mutations in ANXA11 and similar clinical presentations from a large neurodegenerative disease cohort, thereby establishing CBS as part of the phenotypic spectrum of ANXA11 mutations. Here, ANXA11 is linked to neurodegenerative disease.